Suppliers and packagers for dotarem

dotarem

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Guerbet	DOTAREM	gadoterate meglumine	SOLUTION;INTRAVENOUS	204781	NDA	Guerbet LLC	67684-2000-0	10 VIAL in 1 PACKAGE (67684-2000-0) / 5 mL in 1 VIAL	2013-03-20
Guerbet	DOTAREM	gadoterate meglumine	SOLUTION;INTRAVENOUS	204781	NDA	Guerbet LLC	67684-2000-1	10 VIAL in 1 PACKAGE (67684-2000-1) / 10 mL in 1 VIAL	2013-03-20
Guerbet	DOTAREM	gadoterate meglumine	SOLUTION;INTRAVENOUS	204781	NDA	Guerbet LLC	67684-2000-2	10 VIAL in 1 PACKAGE (67684-2000-2) / 15 mL in 1 VIAL	2013-03-20
Guerbet	DOTAREM	gadoterate meglumine	SOLUTION;INTRAVENOUS	204781	NDA	Guerbet LLC	67684-2000-3	10 VIAL in 1 PACKAGE (67684-2000-3) / 20 mL in 1 VIAL	2013-03-20
Guerbet	DOTAREM	gadoterate meglumine	SOLUTION;INTRAVENOUS	204781	NDA	Guerbet LLC	67684-2000-4	6 VIAL in 1 PACKAGE (67684-2000-4) / 100 mL in 1 VIAL	2013-03-20
Guerbet	DOTAREM	gadoterate meglumine	SOLUTION;INTRAVENOUS	204781	NDA	Guerbet LLC	67684-2000-0	10 VIAL in 1 PACKAGE (67684-2000-0) / 5 mL in 1 VIAL	2013-04-26

Dotarem Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for Dotarem (gadoteric acid), a gadolinium-based contrast agent used in medical imaging. The analysis focuses on key suppliers of active pharmaceutical ingredients (APIs), manufacturing capabilities, and regulatory considerations impacting the availability and cost of Dotarem.

What is Dotarem and What is Its Market Significance?

Dotarem, marketed by Guerbet, is an intravenous contrast agent used in magnetic resonance imaging (MRI) and computed tomography (CT) scans to enhance the visibility of internal body structures. Its primary active ingredient is gadoteric acid, a macrocyclic gadolinium complex known for its stability and low risk of dissociation, which is crucial for patient safety given the toxicity of free gadolinium.

The global market for contrast media is significant, driven by the increasing prevalence of chronic diseases, aging populations, and advancements in medical imaging technology. Dotarem holds a notable share within this market, particularly in regions with strong adoption of MRI and CT procedures. The drug's efficacy in visualizing pathologies such as tumors, vascular abnormalities, and inflammatory lesions contributes to its clinical utility and commercial demand.

Who Are the Primary API Suppliers for Gadoteric Acid?

The synthesis of gadoteric acid is a complex chemical process requiring specialized expertise and manufacturing infrastructure. While Guerbet is the primary marketer of the finished drug product, the sourcing of the Active Pharmaceutical Ingredient (API) is a critical element of its supply chain. The identity of direct API manufacturers for gadoteric acid is often proprietary. However, based on industry understanding and patent landscapes, key considerations for API sourcing include:

• Specialty Chemical Manufacturers: Companies with expertise in complex organic synthesis and the handling of rare earth elements are potential suppliers. These entities typically operate under stringent quality control and regulatory oversight.
• Contract Manufacturing Organizations (CMOs): Pharmaceutical companies often partner with CMOs to produce APIs. These CMOs must possess Good Manufacturing Practices (GMP) certification and demonstrate the capability to produce gadoteric acid at commercial scale.
• In-house Manufacturing: While less common for highly specialized APIs like gadoteric acid, some pharmaceutical companies may maintain internal manufacturing capabilities for critical components to ensure supply chain control and intellectual property protection.

The specific suppliers are generally not publicly disclosed by the brand manufacturer to protect competitive advantages and supply chain security. However, the ability to produce macrocyclic gadolinium chelates reliably and to pharmaceutical-grade standards is a prerequisite for any potential supplier.

What are the Manufacturing Processes and Key Players in Dotarem Production?

The manufacturing of Dotarem involves two primary stages: API synthesis and finished drug product formulation.

API Synthesis

The synthesis of gadoteric acid involves several intricate chemical steps. This includes the preparation of the macrocyclic ligand and its subsequent chelation with a gadolinium salt. Key aspects of this stage include:

• Ligand Synthesis: The macrocyclic ligand, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), is a complex organic molecule. Its synthesis requires multi-step reactions and high purity standards.
• Chelation: The DOTA ligand is then reacted with a gadolinium salt (e.g., gadolinium chloride) under controlled conditions to form the gadolinium chelate. This process must ensure complete chelation and minimize the presence of free gadolinium ions.
• Purification: Rigorous purification steps are essential to remove unreacted starting materials, by-products, and any residual free gadolinium. High-performance liquid chromatography (HPLC) and other advanced analytical techniques are employed to confirm purity.

Finished Drug Product Formulation

Once the gadoteric acid API is produced and qualified, it is formulated into the final injectable solution. This stage involves:

• Formulation: The API is dissolved in an aqueous solution, often with excipients to adjust pH, enhance stability, and ensure isotonicity.
• Sterilization: The final product must be sterile to be administered intravenously. This typically involves terminal sterilization or aseptic processing.
• Filling and Packaging: The sterile solution is filled into vials or syringes under aseptic conditions and then packaged for distribution.

Key Players in Manufacturing:

• Guerbet: As the originator and primary marketer, Guerbet holds significant control over its manufacturing processes, either through direct operations or tightly controlled contract manufacturing. They are responsible for ensuring the quality and compliance of the entire supply chain.
• Contract Manufacturing Organizations (CMOs): Guerbet likely partners with specialized CMOs for specific stages of API production or finished product manufacturing. These CMOs must operate under strict GMP guidelines and have established quality agreements with Guerbet. Identifying specific CMOs involved in the Dotarem supply chain is difficult due to confidentiality agreements. However, companies with expertise in sterile injectable manufacturing and complex chemical synthesis are likely candidates.

What are the Regulatory Requirements and Compliance Standards?

The production and distribution of pharmaceutical products like Dotarem are subject to stringent regulatory oversight by health authorities worldwide. Compliance with these standards is paramount for market access and patient safety.

Key Regulatory Bodies and Standards:

• U.S. Food and Drug Administration (FDA): The FDA regulates drugs in the United States, requiring adherence to Current Good Manufacturing Practices (cGMP). This includes inspections of manufacturing facilities, review of drug master files (DMFs) for APIs, and oversight of product quality and labeling.
• European Medicines Agency (EMA): The EMA oversees drug approvals and regulations in the European Union. It enforces EU GMP guidelines and requires detailed documentation on manufacturing processes, quality control, and safety.
• Other National Regulatory Authorities: Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and other national bodies have their own specific regulatory frameworks that manufacturers must meet.
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): ICH guidelines, such as ICH Q7 for API GMP and ICH Q8-Q12 for pharmaceutical development, quality risk management, and quality systems, provide a harmonized framework for global regulatory compliance.

Specific Compliance Considerations for Gadolinium-Based Contrast Agents:

• Gadolinium Purity and Stability: Regulators place a strong emphasis on the purity of the gadolinium chelate and the absence of free gadolinium ions. The stability of the chelate over the product's shelf life is also a critical parameter, as free gadolinium is nephrotoxic and can accumulate in tissues.
• Manufacturing Process Validation: All manufacturing steps, from API synthesis to final product packaging, must be thoroughly validated to ensure consistent quality and efficacy.
• Pharmacovigilance and Post-Market Surveillance: Manufacturers are required to monitor the safety of their products in the post-market setting and report any adverse events to regulatory authorities. This is particularly important for contrast agents due to the potential for hypersensitivity reactions and concerns regarding gadolinium retention.
• Supply Chain Security and Traceability: Robust systems for supply chain management, including raw material sourcing, manufacturing, and distribution, are necessary to prevent counterfeiting and ensure product integrity.

The regulatory landscape for gadolinium-based contrast agents has evolved. Concerns regarding gadolinium deposition have led to increased scrutiny and, in some jurisdictions, restrictions on the use of certain less stable linear agents. Dotarem, being a macrocyclic agent, generally benefits from a more favorable safety profile in this regard, but continuous adherence to evolving regulatory expectations is vital.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The global supply chain for pharmaceuticals is susceptible to various risks that can impact product availability, cost, and quality. For Dotarem, these risks include:

Raw Material Sourcing:

• Limited Gadolinium Sources: Gadolinium is a rare earth element, and its mining and processing are concentrated in a few regions globally. Disruptions in mining operations or geopolitical instability in these regions can affect the availability and price of gadolinium salts.
• Specialized Ligand Precursors: The synthesis of the DOTA ligand requires specific chemical precursors. Dependency on a limited number of suppliers for these precursors can create vulnerabilities.

Mitigation Strategies:

• Diversification of Suppliers: Identifying and qualifying multiple sources for critical raw materials, including gadolinium salts and ligand precursors, can reduce reliance on single suppliers.
• Long-Term Contracts: Negotiating long-term supply agreements with key raw material providers can ensure price stability and guaranteed supply.
• Inventory Management: Maintaining strategic safety stock of critical raw materials can buffer against short-term supply disruptions.

Manufacturing Capacity and Geopolitical Factors:

• Concentration of Manufacturing: If key API or finished product manufacturing is concentrated in a single facility or geographic region, it becomes vulnerable to local disruptions (e.g., natural disasters, political unrest, pandemics).
• Trade Wars and Tariffs: Geopolitical tensions can lead to trade restrictions, tariffs, and increased costs for imported raw materials or finished goods.

Mitigation Strategies:

• Dual Sourcing of Manufacturing: Establishing manufacturing partnerships with CMOs in different geographic regions can provide redundancy.
• Geographic Diversification: Evaluating and selecting manufacturing sites that are less prone to regional disruptions.
• Monitoring Geopolitical Landscape: Proactive monitoring of international relations and trade policies that could impact supply chains.

Regulatory Changes and Scrutiny:

• Evolving Safety Concerns: Increased regulatory focus on gadolinium retention and long-term safety could lead to new guidelines or restrictions on certain gadolinium-based contrast agents.
• Stricter GMP Enforcement: Regulatory agencies continuously enhance their GMP inspection rigor, which could lead to temporary plant shutdowns or product recalls if deficiencies are found.

Mitigation Strategies:

• Proactive Regulatory Engagement: Maintaining open communication with regulatory authorities and staying abreast of emerging safety concerns and guidelines.
• Robust Quality Management Systems: Implementing and continuously improving comprehensive quality management systems that exceed regulatory minimums.
• Investment in R&D: Investing in research to further understand gadolinium dynamics and potentially develop even safer contrast agents.

Intellectual Property and Competition:

• Patent Expirations: As patents expire, generic competition can emerge, potentially impacting pricing and market share. However, the complexity of manufacturing and regulatory hurdles for gadolinium agents can delay or limit generic entry.
• Process Patents: Manufacturers may rely on process patents to maintain a competitive edge. Changes in patent law or challenges to existing patents can affect market exclusivity.

Mitigation Strategies:

• Continuous Innovation: Investing in the development of next-generation contrast agents or improved formulations.
• Strategic Patent Portfolio Management: Actively managing and defending intellectual property rights.

Key Takeaways

• Dotarem's supply chain relies on specialized synthesis of gadoteric acid, a process demanding high purity and stringent quality control.
• Key API and finished product suppliers are likely highly specialized chemical manufacturers and contract manufacturing organizations (CMOs) operating under strict GMP regulations, with specific entities often remaining proprietary.
• Global regulatory bodies, including the FDA and EMA, impose rigorous compliance standards, particularly concerning gadolinium purity, stability, and absence of free ions.
• Supply chain risks include raw material availability (gadolinium, ligand precursors), manufacturing concentration, geopolitical factors, evolving regulatory scrutiny on gadolinium safety, and competitive pressures from patent expirations.
• Mitigation strategies involve supplier diversification, long-term contracts, strategic inventory management, geographic diversification of manufacturing, proactive regulatory engagement, robust quality systems, and continuous innovation.

Frequently Asked Questions

1. Are there publicly listed suppliers for Dotarem's active pharmaceutical ingredient (API)? Publicly listed suppliers for the specific API (gadoteric acid) for Dotarem are not disclosed by the marketing company, Guerbet, due to commercial confidentiality and supply chain security protocols.

2. What is the typical lead time for sourcing critical raw materials for gadoteric acid synthesis? Lead times for specialized chemical precursors and rare earth elements like gadolinium can range from several weeks to several months, depending on supplier capacity, order volume, and global supply chain conditions.

3. How does the regulatory status of macrocyclic versus linear gadolinium contrast agents affect Dotarem's supply chain? Dotarem, as a macrocyclic agent, generally faces less regulatory pressure concerning gadolinium retention compared to some linear agents. This stability profile simplifies certain regulatory compliance aspects of its supply chain, as the risk of dissociation is inherently lower.

4. What impact do geopolitical tensions in rare earth mining regions have on Dotarem's supply? Geopolitical tensions or supply disruptions in regions that are major sources of rare earth elements, including gadolinium, can lead to price volatility and potential shortages of the raw material, impacting the cost and availability of Dotarem production.

5. Can patent expirations for Dotarem lead to immediate generic competition and supply chain shifts? While patent expirations can open the door for generics, the complex manufacturing process for gadoteric acid and the stringent regulatory approval pathway for contrast agents often create significant barriers and long lead times for generic market entry, thereby influencing the pace of supply chain shifts.

Citations

[1] European Medicines Agency. (n.d.). Guideline on the requirements for the use of non-biological complex medicinal products (NBCMPs) in clinical trials. EMA. [2] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. FDA. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. ICH. [4] U.S. Food and Drug Administration. (2018, September 18). FDA Drug Safety Communication: FDA clarifies gadolinium-based contrast agent recommendations for patients. FDA. [5] Guerbet. (n.d.). Dotarem® (gadoterate meglumine) for injection. Guerbet.